
STAT Plus: Top FDA official: Agency needs to start using accelerated approval for gene therapies
FDA's Peter Marks said the oft-debated path used for some cancer drugs should be extended to gene therapies for rare diseases.
Read The StoryInside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
FDA's Peter Marks said the oft-debated path used for some cancer drugs should be extended to gene therapies for rare diseases.
Read The Storyadvertisement